|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-12-16
|
|
pubmed:abstractText |
The applicability of islet transplantation as treatment for type 1 diabetes is limited by long-term graft dysfunction, immunosuppressive drug toxicity, need for multiple donors, and increased risk of allosensitization. We describe two immunosuppressive regimens based on the costimulation blocker belatacept (BELA) or the antileukocyte functional antigen-1 antibody efalizumab (EFA), which permit long-term islet allograft survival and address some of these concerns.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
pubmed-author:AminRajR,
pubmed-author:BluestoneJeffrey AJA,
pubmed-author:FongLawrenceL,
pubmed-author:FrassettoLynda ALA,
pubmed-author:KerlanRobert KRK,
pubmed-author:MasharaniUmeshU,
pubmed-author:McElroyJoanJ,
pubmed-author:PosseltAndrew MAM,
pubmed-author:RamosMarissa DMD,
pubmed-author:StockPeter GPG,
pubmed-author:SzotGregory LGL,
pubmed-author:TavakolMehdiM,
pubmed-author:VincentiFlavioF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
27
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1595-601
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20978464-Antibodies, Monoclonal,
pubmed-meshheading:20978464-Antigens, CD11,
pubmed-meshheading:20978464-Awareness,
pubmed-meshheading:20978464-Cell Adhesion,
pubmed-meshheading:20978464-Diabetes Mellitus, Type 1,
pubmed-meshheading:20978464-Humans,
pubmed-meshheading:20978464-Hypoglycemia,
pubmed-meshheading:20978464-Hypoglycemic Agents,
pubmed-meshheading:20978464-Immunoconjugates,
pubmed-meshheading:20978464-Immunosuppressive Agents,
pubmed-meshheading:20978464-Insulin,
pubmed-meshheading:20978464-Islets of Langerhans Transplantation
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.
|
|
pubmed:affiliation |
Transplant Division, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143-0790, USA. andrew.posselt@ucsfmedctr.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
